Endovascular manipulation to restrict restenosis

Vascular Medicine

Volumn 3, Issue 3, 1998, Pages 177-188

  Gershlick, A H ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Local drug delivery devices; Restenosis; Stents

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CYTOCHALASIN B; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRINOGEN RECEPTOR AFFECTING AGENT; HEPARIN; IRIDIUM 192; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE; PHOSPHORUS 32; STRONTIUM 90; UROKINASE; VASCULOTROPIN;

ARTICLE; BALLOON CATHETER; BLEEDING; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; HUMAN; INTERVENTIONAL RADIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 0031796969     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9800300302     Document Type: Article

References (86)

1. Moore RS, Rutty G, Underwood MJ et al. Time sequence of vessel wall changes in an experimental model of angioplasty J Pathol 1994; 172 287-92.
2. Carter AJ, Laird JR, Farb A et al. Morphological characteristics of lesion formation and lime course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994; 24 1398-405.
3. Waller BF, Johnson DE, Schnitt SJ et al. Histologic analysis of directional coronary atherectomy samples A review of findings and their clinical relevance Am J Cardiol 1993; 72: 80E-87E.
4. O'Brien ER, Bennett KL, Garvin MR et al. Betaig-h3, a transforming growth factor beta inducible gene is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol 1996; 16: 576-84.
5. Grant MB, Wargovich TJ, Ellis EA et al. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. Regul Pept 1996; 67: 137-44.
6. Marmur JD, Poon M, Rossikhina M, Taubman MB Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 1992; 86 (6 suppl). 11153-60
7. Strauss BH, Robinson R, Batchelor WB et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996; 79: 541-50.
8. Topol EJ, Califf RM, Weisman HF et al. Randomised trail of coronary intervention with antibody against IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343; 881-86
9. Mintz GS, Popma JJ, Pichard AD. Mechanisms of late arterial responses to transcatheter therapy: a serial quantitative angiographic and intravascular study. Circulation 1994; 90 (suppl): I-24
10. Carter AJ, Laird JR, Kufs WM et al. Coronary stenting with a novel stainless steel balloon-expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. J Am Coll Cardiol 1996; 27: 1270-77.
11. Mintz GS, Popma JJ, Hong MK et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996; 78: 18-22.
12. Serruys PW, de Jaegere P, Kiemeneij F et al. For the Benestent group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 1994; 331: 489-95.
13. Fischman D, Leon M, Baim D et al. A randomised comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
14. Klugherz BD, deAngelo DL, Kim BK et al. Three year follow up after Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 1185-91.
15. Eeckout E, van Melle G, Stauffer JC et al. Can early closure and restenosis after endoluminal stenting be predicted from clinical, procedural, and angiographic variables at the time of intervention. Br Heart J 1995; 74: 592-97.
16. Wong SC, Baim DS, Schatz RA et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter US Palmaz-Schatz experience. J Am Coll Cardiol 1995; 26: 704-12.
17. Foley JB, Brown RI, Penn IM. Thrombosis and restenosis after stenting in failed angioplasty: comparison with elective stenting Am Heart J 1994; 128: 12-20.
18. Nunes G, Pinto I, Matters L et al. Coronary stenting in vessels smaller than 3mm is associated with higher restenosis rates. Eur Heart J 1996; 17: 173 (abstract).
19. Moscucci M, Piana RN, Kuntz RE. Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy Am J Cardiol 1994; 73: 1147-53.
20. Rogers C, Edelman ER. Endovascular stem design dictates experimental restenosis and thrombosis. Circulation 1995; 91: 2995-3001.
21. Yokoi H, Kimura T, Nakagawa Y et al. Long-term clinical and quantitative angiographic follow-up after the Palmaz-Schatz. J Am Coll Cardiol 1996; 272 (2 suppl A): 224A
22. Baim DS, Lavine MJ, Leon MB et al. Management of restenosis within the Palmaz-Schatz coronary artery stent (the US multicenter experience). Am J Cardiol 1993; 71: 364-66.
23. Schwartz L, Lesperance J, Bourassa MG et al. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990; 119: 232-36.
24. Serruys PW, Rutsch W, Heyndrickx GR et al Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. Circulation 1991; 84: 1568-80.
25. Serruys PW, Klein W, Tijssen JP et al Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Circulation 1993; 88: 1588-1601.
26. Karsch KR, Presack MB, Baildon R et al Low molecular weight heparin (reviparin) in transluminal coronary angioplasty. Results of a randomised, double blind, unfractionated heparin and placebo-controlled, multicentre trial (REDUCE Trial) J Am Coll Cardiol 1996; 28: 1437-43.
27. Cairns JA, Gill J, Morton B et al. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR study. Circulation 1996; 94 1553-60.
28. Foley DP, Serruys PW. Fluvasiatin for the prevention of restenosis after coronary balloon angioplasty, angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Br J Clin Pract 1996; 77 A (suppl): 40-53.
29. Maresta A, Balducelli M, Cantini L et al Trapidil (triazolpyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomised double-blind STARC study. Circulation 1994; 90: 2710-2715.
30. Emanuelson H, Beatt KJ, Bagger JP et al. Long term effects of angiopeptin treatment in coronary angioplasty Reduction of clinical events but not angiographic restenosis. Circulation 1995; 91: 1689-96.
31. Hoberg E, Kubler W. Prevention of restenosis after PTCA: role of calcium antagonists. J Cardiovasc Pharmacol 1991; 18 (suppl). S15-S19
32. Anonymous. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group Circulation 1992; 86: 100-10.
33. Serruys PW, Foley DP, Kirkeeide RL, King SB III Restenosis revisited: insights provided by quantitative coronary angiography. Am Heart J 1993; 126: 1243-67.
34. Clowes AW, Karnowski MJ Supression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-26.
35. Brack MJ, Ray S, Chauhan A, et al. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome J Am Coll Cardiol 1995; 26: 947-54.
36. Powell JS, Clozel, Muller RKM et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-88.
37. Gellman J, Ezekowitz MD, Sarembock IJ et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolaemic rabbit. J Am Coll Cardiol 1991; 17: 251-59.
38. Sarembock IJ, Gertz SD, Gimple LW et al. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243.
39. Serruys PW, Herrman JPR, Simon R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. The HELVETICA trial. N Engl J Med 1995; 333: 757-63.
40. Hofling B, Huens TY. Intravascular local drug delivery after angioplasty. Eur Heart J 1995; 16: 437-40.
41. Mitchel JF, Azrin MA, Fram DB et al. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 1994; 90: 1979-88.
42. Reissen R, Rahimizadeh H, Blessing E et al. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 1993; 4: 749-58.
43. Meyer BJ, Fernandez-Ortiz A, Mailhac A et al Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombus and minimizes platelet deposition after angioplasty Circulation 1994; 90: 2474-80
44. More RS, Brack MJ, Underwood M, Gershlick AH. Comparative study of two local delivery balloons in a model of angioplasty. Eur Heart J 1993; 14: 202 (abstract).
45. Michel JF, Fram DB, Palme DF et al Enhanced intracoronary thrombolysis with urokinase using a novel local drug delivery system. In vitro, in vivo and clinical studies. Circulation 1995; 91: 785-93
46. Camenzid E, Kint PP, Di Mario C et al. Intracoronary heparin delivery in humans Acute feasibility and long term results. Circulation 1995; 92: 2463-72.
47. Tahlil O, Brami M, Feldman LJ et al The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33: 181-87
48. Gunn J, Holt L, Shepard H et al Local delivery of antisense oligonucleotide via a double skinned porous balloon: where does the drug go? Eur Heart J 1995; 16: 484 (abstract).
49. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery J Am Coll Cardiol 1990; 15: 475-81.
50. Hong MK, Wong SC, Farb A et al. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery Coron Artery Dis 1993; 4: 1023-27.
51. Cumberland DC, Gunn J, Tsikaderis D et al. Initial experience of local drug delivery via a porous balloon during percutaneous angioplasty. J Am Coll Cardiol 1994; 23 186A (abstract).
52. Martin W, Aggarwal R, Salame M et al. Efficiency of local delivery of anti-platelet derived growth factor-BB antibody into injured arterial vessel by microporous balloon. Heart 1997; 77: 22 (abstract)
53. Fernandez-Ortiz A, Meyer BJ, Mailhac A et al. A new approach for local intravascular drug delivery. Iontophoretic balloon. Circulation 1994; 89: 1518-22.
54. Gonschior P, Pahl C, Huens TY et al Comparison of local intravascular drug-delivery catheter systems. Am Heart J 1995; 130: 1174-81.
55. Gonschior P, Goetz AE, Huens TY, Hoffling B. A new catheter for prolonged local drug application. Coron Artery Dis 1995; 6: 329-34.
56. Baek SH, Mehdi K, Gunn J et al. Adventitia is the predominant site of antisense-c-myc delivery to porcine coronary arteries by each of four endovascular delivery catheters. J Am Coll Cardiol 1997; 29: 201A (abstract).
57. Camenzid E, Schaar M, Bakker W et al. Scintigraphic comparison of local delivery efficiency of two delivery catheters (Dispatch versus Channel balloon) following balloon angioplasty in humans. Circulation Suppl 1996; 94: 15: I-202 (abstract).
58. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microspheres via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J 1991; 122: 1136-40
59. Guznman LA, Labhasetwar V, Song C et al. Local infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty Circulation 1996; 94: 1441-48.
60. More RS, Underwood MJ, Brack MJ, Pringle S, de Bono DP, Gershlick AH. In vitro studies of a bispecific monoclonal antibody antithrombotic conjugate [ATC(3)]. Int J Angiol 1995; 4: 83-87.
61. More RS, Underwood MJ, Brack MJ, Pringle S, de Bono DP, Gershlick AH. A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation. Cardiovasc Res 1993; 27(12): 2200-204.
62. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997; 336: 1689-96.
63. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury Proc Natl Acad Sci USA 1990; 87: 3773-77.
64. Oberhoff M, Baumbach A, Rubsamen K et al Delivery of low molecular weight heparin into coronary arteries of dogs using a porous balloon catheter Eur Heart J 1994; 15: 560 (abstract).
65. Camenzind E, Legrand V, Vrolix M et al. An open multicenter registry to evaluate local heparin delivery following balloon angioplasty for the prevention of restenosis: preliminary results. J Am Coll Cardiol 1996; 27: 321 (abstract).
66. Nunes GL, Hanson SR, King SB et al Local delivery of a synthetic antithrombin with a hydrogel coated angioplasty balloon catheter inhibits platelet dependant thrombus. J Am Coll Cardiol 1994; 23: 1578-83.
67. Steg PG, Feldman LJ, Scoazec JY et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994; 90: 1648-56.
68. Flaherty D, Zengxan N, van Pelt N et al. Overexpression of human constitutive nitric oxide synthase gene reduces neointimal formation in balloon-injured rat carotid arteries Circulation 1996; 94 I-590 (abstract).
69. Simons M, Edelman ER, deKeyser J-L et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo Nature 1992; 359: 67-70.
70. McEwan, Henney A, Humphries S. Vascular disease the next target for local molecular therapies. BMJ 1994; 308: 995-96.
71. Gunn J, Holt CM, Francis SE et al. The effect of oligonucloetides to c-myb on vascular smooth muscle cell proliferation and neointimal formation after porcine coronary angioplasty. Circ Res 1997; 80: 520-31.
72. Villa AE, Guzman LA, Poptic EJ et al Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury Circ Res 1995; 76: 505-13.
73. Kuntz RE, Gibson CM, Nobuyoshi M et al. Generalised model of restenosis after conventional balloon angioplasty stenting and directional atherectomy. J Am Coll Cardiol 1993; 21: 15-25
74. Carter AJ, Laud JR, Farb A et al Morphological characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994, 24: 1398-405.
75. van Beusekom HM, van der Giessen, van Suylen R et al. Histology after stenting of human saphenous vein bypass grafts, observations from surgically excised grafts 3-320 days after stent implantation J Am Coll Cardiol 1993; 21: 45-54.
76. Kearney M, Pieczek A, Haley L et al. Histopathology of in stent restenosis in patients with peripheral vascular disease. Circulation 1997; 95: 1998-2002
77. Fischell TA, Kharma BK, Fischell DR et al. Low dose, beta-particle emmission from 'stent' wires results in complete, localized inhibition of smooth muscle cell proliferation. Circulation 1994; 90 2956-63.
78. Waksman R, Robinson KA, Crocker IR et al. Intravascular radiation before stent implantation inhibits neointimal formation in stented porcine coronary arteries. Circulation 1995; 93: 1383-86.
79. Carter AJ, Laird JR, Bailley LR et al Effects of endovascular radiation from a beta-particle emitting stent in a porcine coronary stenosis model a dose response study Circulation 1996; 94: 2364-68
80. Popowski Y, Verin V, Urban P. Endovascular beta-irradiation after percutaneous transluminal coronary balloon angioplasty Int J Radiat Oncol Biol Phys 1996; 36: 841-45
81. Teirsten PS, Massuillo V, Jani S et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697-703
82. Mazur W, Ali MN, Khan MM et al. High dose intracoronary radiation for inhibition of neointimal formation in the stented and balloon injured porcine models of restenosis: angiographic, morphometric, and histopathologic analyses. Int J Radiat Oncol Biol Phys 1996; 36: 777-88
83. Aggarwal RK, Ireland DC, Azrin MA et al. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 1996; 94: 3311-17.
84. Matsuno H, Stassen JM, Vermylen J et al Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-206.
85. Baron JH, Aggrawal R, de Bono DP, Gershlick AH. Absorption and elution of c7E3 Fab from polymer-coated stems in-vitro. Eur Heart J 1997; 18 503.
86. Baron JH, Aggrawal R, de Bono DP, Gershlick AH c7E3 Fab inhibits adhesion of smooth muscle cells to vitronectin: a possible way of inhibiting in-stent restenosis Eur Heart J 1997; 18: 500